
Fast and effective diagnostic testing for the emergency department
No shift in the emergency department is ever the same. But some days are more daunting than others. When you have an acutely ill patient with a suspected infectious illness, there are so many unknowns. Should the patient be admitted? Isolated? Given antibiotics? To answer these questions, you need a diagnosis.
And now you don’t need to wait for one. With QIAstat-Dx panel tests, you get results for several common pathogens in about an hour. Whether it’s a suspected respiratory, gastrointestinal or central nervous system infection, we have you covered. Don’t wait. React faster, test for symptoms and expedite emergency care with QIAstat-Dx.
Why is the QIAstat-Dx ideal for emergency care?
Fast answers for 3 challenging syndromes
QIAstat-Dx is proven to enhance patient flow through the ER
For patients in the ER with respiratory symptoms, QIAstat-Dx has been shown to (6):
- Reduce the time to diagnosis by 92% (QIAstat-Dx: 1.7 hours, Traditional batch PCR: 21.3 hours)
- Reduce the time patients spent in assessment areas by 72% (QIAstat-Dx: 8 hours, Traditional batch PCR: 28.8 hours)
- Increase the percentage of patients who were transferred from the ER directly to a definitive care area (QIAstat-Dx: 14% of patients, Traditional batch PCR: 0% of patients)
It doesn’t get easier than this – the QIAstat-Dx workflow
Stay connected to your testing no matter where you are
More to explore
FAQ
References
- Leber, A. L., et aI. (2020) Journal of clinical microbiology, 58(5), e00155-20
- Hannet I, Engsbro AL, Pareja J, et al. Eur J Clin Microbiol Infect Dis. 2019;38(11):2103-2112. doi:10.1007/s10096-019-03646-4
- QIAstat-Dx Respiratory SARS-CoV-2 Panel V2 Instructions for Use (Handbook). August 2022.
- QIAstat-Dx Gastrointestinal Panel 2 Instructions for Use (Handbook). February 2023.
- QIAstat-Dx ME Panel Instructions for Use (Handbook). September 2022.
- Brendish, N.J. et al. (2020) Lancet Respir. Med. 8(12):1192–120
- Castany-Feixas, M. et al. (2021) Eur. J. Clin. Microbiol. Infect. Dis. 40(10), 2153–2160
* QIAstat-Dx Respiratory SARS-CoV-2 Panel:
PPA: 97.13% (95% CI, 96.42%–97.73%)
NPA: 99.80% (95% CI, 99.76%–99.84%)
QIAstat-Dx Gastrointestinal Panel 2:
PPA: 96.7 (95% CI, 96.0%–97.4%)
NPA: 99.9 (95% CI, 99.86%–99.92%)
QIAstat-Dx Meningitis/Encephalitis Panel:
PPA: 95.24% ( 90.50%–97.67%)
NPA: 99.93% (99.84%–99.97%)
See the respective panel handbook for more details.
** Some features require a QIAstat-Dx Connectivity plan. For example, access to the QIAsphere Insights dashboard requires a QIAstat-Dx Connectivity plan. Flexible plans are available to meet your needs.
QIAsphere data is aggregated from QIAsphere-connected QIAstat-Dx instruments.
For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit instructions for use or user manual. QIAGEN instructions for use and user manuals are available at www.qiagen.com or can be requested from QIAGEN Technical Services (or your local distributor.


